Alias
科研级 Ontuxizumab ( 昂妥昔珠单抗 ), Anti-CD248 Recombinant Antibody, Research Grade Ontuxizumab
Molecular Name
Ontuxizumab
Applications
Neut, ELISA, IF, IP, FuncS, FC, ICC
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
CD248[Homo sapiens]
Sequence
Please contact our sales representative to learn more information about this reagents.
Background
Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248). Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma. This drug was developed by Morphotek and Ludwig Institute for Cancer Research.
Storage
该产品可在 2°C-8°C 下保存一个月,活性不会明显降低。在 -20°C 至 -80°C 下保存,可稳定保存十二个月。避免反复冻融,用冰袋运输。